Open AccessPrior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab
Author(s) -
Nicholas Costable,
Zachary A. Borman,
Jiayi Ji,
Marla Dubinsky,
Ryan C. Ungaro
Publication year - 2021
Publication title -
digestive diseases and sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 124
eISSN - 1573-2568
pISSN - 0163-2116
DOI - 10.1007/s10620-021-07046-7
Subject(s) - vedolizumab , ustekinumab , medicine , immunogenicity , inflammatory bowel disease , tumor necrosis factor alpha , antibody , immunology , infliximab , disease
Patients with inflammatory bowel disease (IBD) on biologic therapy may lose response to anti-tumor necrosis factor agents (anti-TNFs) due to the development of anti-drug antibodies (ADAs). A history of anti-TNF ADA increases the risk of developing ADA to subsequent anti-TNFs; however, it is not known whether ADA to anti-TNFs increases the risk of ADA development to vedolizumab (VDZ) or ustekinumab (UST). We aimed to investigate whether prior history of ADA to anti-TNF increases the risk of ADA to VDZ and UST.